Fireside Chat: Defining the Next Frontier of RNAi Therapeutics to Target Beyond the Liver

• Examining why extrahepatic delivery is the field’s defining challenge
• Focusing investment and research on the right bottlenecks
• Defining the milestones that will signal the arrival of truly routine extrahepatic RNAi delivery

Speakers:

David Jackson

Chief Executive Officer

Ceria Therapeutics

Paul Lawrence

Executive Director of Bioscience Research

Biocogent